BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

...N.V. market Aptheal amlexanox for aphthous ulcers. Uluru also markets OraDisc A, amlexanox delivered with Atrix’s...
BioCentury | Jun 11, 2012
Company News

Medigene, Cowen Healthcare Royalty Partners L.P. deal

...hormone-releasing hormone (LHRH) agonist. MediGene had European rights to Eligard under a 2001 deal with Atrix Laboratories Inc....
BioCentury | Feb 14, 2011
Company News

Valeant Pharmaceuticals, Allergan sales and marketing update

...TSX:QLT; NASDAQ:QLTI, Vancouver, B.C.) in 2008. QLT gained the product through its 2004 acquisition of Atrix Laboratories Inc....
BioCentury | Jan 24, 2011
Company News

Astellas, Tolmar sales and marketing update

...million). MediGene had European rights to the prostate cancer drug under a 2001 deal with Atrix Laboratories Inc....
BioCentury | Jul 26, 2010
Company News

MediGene, Astellas sales and marketing update

...royalties. MediGene had European rights to the prostate cancer drug under a 2001 deal with Atrix Laboratories Inc....
BioCentury | Sep 10, 2007
Clinical News

Eligard leuprolide acetate regulatory update

...is a luteinizing hormone-releasing hormone (LHRH) agonist delivered using the Atrigel system QLT acquired with Atrix Laboratories Inc....
BioCentury | May 28, 2007
Company News

Zila board of directors update

...Inc. (ZILA), Phoenix, Ariz. Business: Dental, Diagnostic Appointed: David Bethune, former chairman and CEO of Atrix Laboratories Inc....
BioCentury | Feb 12, 2007
Company News

QLT, sanofi-aventis, Takeda, Tap Holdings, Wako Pure Chemical cancer news

...prostate cancer drug Eligard leuprolide acetate. In 2003, Takeda, Tap and Wako filed suit against Atrix...
BioCentury | Feb 10, 2007
Company News

QLT, sanofi-aventis settle Eligard lawsuit

...In 2003, Takeda (Tokyo:4502), Tap (Lake Forest, Ill.) and Wako (Osaka, Japan) filed suit against Atrix...
BioCentury | Dec 11, 2006
Clinical News

Eligard leuprolide acetate regulatory update

...are approved in the EU. In 2001, MDG acquired exclusive European rights to Eligard from Atrix...
Items per page:
1 - 10 of 317
BioCentury | Jan 31, 2018
Distillery Therapeutics

Cancer

...N.V. market Aptheal amlexanox for aphthous ulcers. Uluru also markets OraDisc A, amlexanox delivered with Atrix’s...
BioCentury | Jun 11, 2012
Company News

Medigene, Cowen Healthcare Royalty Partners L.P. deal

...hormone-releasing hormone (LHRH) agonist. MediGene had European rights to Eligard under a 2001 deal with Atrix Laboratories Inc....
BioCentury | Feb 14, 2011
Company News

Valeant Pharmaceuticals, Allergan sales and marketing update

...TSX:QLT; NASDAQ:QLTI, Vancouver, B.C.) in 2008. QLT gained the product through its 2004 acquisition of Atrix Laboratories Inc....
BioCentury | Jan 24, 2011
Company News

Astellas, Tolmar sales and marketing update

...million). MediGene had European rights to the prostate cancer drug under a 2001 deal with Atrix Laboratories Inc....
BioCentury | Jul 26, 2010
Company News

MediGene, Astellas sales and marketing update

...royalties. MediGene had European rights to the prostate cancer drug under a 2001 deal with Atrix Laboratories Inc....
BioCentury | Sep 10, 2007
Clinical News

Eligard leuprolide acetate regulatory update

...is a luteinizing hormone-releasing hormone (LHRH) agonist delivered using the Atrigel system QLT acquired with Atrix Laboratories Inc....
BioCentury | May 28, 2007
Company News

Zila board of directors update

...Inc. (ZILA), Phoenix, Ariz. Business: Dental, Diagnostic Appointed: David Bethune, former chairman and CEO of Atrix Laboratories Inc....
BioCentury | Feb 12, 2007
Company News

QLT, sanofi-aventis, Takeda, Tap Holdings, Wako Pure Chemical cancer news

...prostate cancer drug Eligard leuprolide acetate. In 2003, Takeda, Tap and Wako filed suit against Atrix...
BioCentury | Feb 10, 2007
Company News

QLT, sanofi-aventis settle Eligard lawsuit

...In 2003, Takeda (Tokyo:4502), Tap (Lake Forest, Ill.) and Wako (Osaka, Japan) filed suit against Atrix...
BioCentury | Dec 11, 2006
Clinical News

Eligard leuprolide acetate regulatory update

...are approved in the EU. In 2001, MDG acquired exclusive European rights to Eligard from Atrix...
Items per page:
1 - 10 of 317